Tezcan O - Search Results

1

Effect of Cellular and Microenvironmental Multidrug Resistance on Tumor-Targeted Drug Delivery in Triple-Negative Breast cancer.

Tezcan O, Elshafei AS, Benderski K, Rama E, Wagner M, Moeckel D, Pola R, Pechar M, Etrych T, von Stillfried S, Kiessling F, Weiskirchen R, Meurer S, Lammers T. Tezcan O, et al. J Control Release. 2023 Feb;354:784-793. doi: 10.1016/j.jconrel.2022.12.056. Epub 2023 Jan 28. J Control Release. 2023. PMID: 36599395 Free PMC article.

2

Differential regulation of Lipocalin 2 (LCN2) in doxorubicin-resistant 4T1 triple negative breast cancer cells.

Meurer SK, Tezcan O, Lammers T, Weiskirchen R. Meurer SK, et al. Among authors: tezcan o. Cell Signal. 2020 Oct;74:109731. doi: 10.1016/j.cellsig.2020.109731. Epub 2020 Aug 3. Cell Signal. 2020. PMID: 32758668

3

Targeting cellular and microenvironmental multidrug resistance.

Tezcan O, Ojha T, Storm G, Kiessling F, Lammers T. Tezcan O, et al. Expert Opin Drug Deliv. 2016 Sep;13(9):1199-202. doi: 10.1080/17425247.2016.1214570. Epub 2016 Aug 5. Expert Opin Drug Deliv. 2016. PMID: 27461854 Free PMC article.

4

Overcoming multidrug resistance using folate receptor-targeted and pH-responsive polymeric nanogels containing covalently entrapped doxorubicin.

Chen Y, Tezcan O, Li D, Beztsinna N, Lou B, Etrych T, Ulbrich K, Metselaar JM, Lammers T, Hennink WE. Chen Y, et al. Among authors: tezcan o. Nanoscale. 2017 Jul 27;9(29):10404-10419. doi: 10.1039/c7nr03592f. Nanoscale. 2017. PMID: 28702658

5

Vimentin silencing effect on invasive and migration characteristics of doxorubicin resistant MCF-7 cells.

Tezcan O, Gündüz U. Tezcan O, et al. Biomed Pharmacother. 2014 Apr;68(3):357-64. doi: 10.1016/j.biopha.2014.01.006. Epub 2014 Feb 13. Biomed Pharmacother. 2014. PMID: 24612689

6

Pancreatic tumor microenvironmental acidosis and hypoxia transform gold nanorods into cell-penetrant particles for potent radiosensitization.

Rauta PR, Mackeyev Y, Sanders K, Kim JBK, Gonzalez VV, Zahra Y, Shohayeb MA, Abousaida B, Vijay GV, Tezcan O, Derry P, Liopo AV, Zubarev ER, Carter R, Singh P, Krishnan S. Rauta PR, et al. Among authors: tezcan o. Sci Adv. 2022 Nov 11;8(45):eabm9729. doi: 10.1126/sciadv.abm9729. Epub 2022 Nov 11. Sci Adv. 2022. PMID: 36367938 Free PMC article.

7

Association of early initiation of dialysis with all-cause and cardiovascular mortality: A propensity score weighted analysis of the United States Renal Data System.

Bozorgmehri S, Aboud H, Chamarthi G, Liu IC, Tezcan OB, Shukla AM, Kazory A, Rupam R, Segal MS, Bihorac A, Mohandas R. Bozorgmehri S, et al. Among authors: tezcan ob. Hemodial Int. 2021 Apr;25(2):188-197. doi: 10.1111/hdi.12912. Epub 2021 Feb 28. Hemodial Int. 2021. PMID: 33644974

8

Hyperbaric Oxygen Preconditioning Provides Preliminary Protection Against Doxorubicin Cardiotoxicity.

Tezcan O, Karahan O, Alan M, Ekinci C, Yavuz C, Demirtas S, Ekinci A, Caliskan A. Tezcan O, et al. Acta Cardiol Sin. 2017 Mar;33(2):150-155. doi: 10.6515/acs20160404b. Acta Cardiol Sin. 2017. PMID: 28344418 Free PMC article.

9

An evaluation of factors affecting clinical outcomes in penetrating cardiac injuries: A single center experience.

Tezcan O, Karahan O, Yavuz C, Demirtaş S, Çalışkan A, Mavitaş B. Tezcan O, et al. Ulus Travma Acil Cerrahi Derg. 2017 Jan;23(1):23-28. doi: 10.5505/tjtes.2016.95994. Ulus Travma Acil Cerrahi Derg. 2017. PMID: 28261766 Free article.

10

Effects of Hyperbaric Oxygen Treatment on Renal System.

Tezcan O, Caliskan A, Demirtas S, Yavuz C, Kuyumcu M, Nergiz Y, Guzel A, Karahan O, Ari S, Soker S, Yalinkilic I, Turkdogan KA. Tezcan O, et al. Iran J Kidney Dis. 2017 Jan;11(1):18-22. Iran J Kidney Dis. 2017. PMID: 28174348

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

24 results

Search Page

Filters